Cipla Fair Value
Cipla (CIPLA) average fair value is ₹1474.82 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹1309.6 (+12.62%), fair value range ₹215.8–₹6238.49. For live price and a broader fundamental view, visit Cipla share price today.
Fair Value Analysis Export
CIPLA Fair Value vs Current Price — Valuation Summary
CIPLA average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). See CIPLA P/B ratio to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Earnings Growth Model (PEG)
Peter Lynch Fair Value
Benjamin Graham Number
Discounted Cash Flow (DCF)
CIPLA Fair Value Analysis — Data Sources & Coverage
Cipla financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine CIPLA earnings report for recent quarterly revenue, profit and EPS trends.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
CIPLA vs Healthcare Sector Peers — P/E, P/B & Market Cap
Cipla P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Par Drugs & Chemical | PAR | 8.09 | 1.06 | ₹113 |
| Accretion Pharmaceuticals | ACCPL | 16.94 | 2.55 | ₹115 |
| Jeena Sikho Lifecare | JSLL | 41.45 | 23.68 | ₹8,396 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| KRM Ayurveda | KRMAYURVED | - | 4.3 | ₹510 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.